DOCSLIB.ORG

Interactions Between Nitrous Oxide and Tissue Plasminogen Activator in a Rat Model of Thromboembolic Stroke

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions Between Nitrous Oxide and Tissue Plasminogen Activator in a Rat Model of Thromboembolic Stroke Interactions between Nitrous Oxide and Tissue Plasminogen Activator in a Rat Model of Thromboembolic Stroke Benoît Haelewyn, Ph.D.,* He´le` ne N. David, Ph.D.,† Nathalie Colloc’h, Ph.D., D.Sc.,‡ Denis G. Colomb, Jr., Ph.D.,§ Jean-Jacques Risso, Ph.D., D.Sc.,ʈ Jacques H. Abraini, Ph.D., D.Sc., Psy.D.# Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/115/5/1044/452771/0000542-201111000-00027.pdf by guest on 25 September 2021 ABSTRACT What We Already Know about This Topic • Whether nitrous oxide, like xenon, reduces of ischemic brain Background: Preclinical evidence in rodents has suggested damage in the setting of thrombolysis for thromboembolic that inert gases, such as xenon or nitrous oxide, may be prom- stroke is unknown. ising neuroprotective agents for treating acute ischemic stroke. This has led to many thinking that clinical trials could be initiated in the near future. However, a recent study has What This Article Tells Us That Is New shown that xenon interacts with tissue-type plasminogen ac- • In rats, when administrated during the ischemic period, nitrous tivator (tPA), a well-recognized approved therapy of acute oxide dose-dependently inhibited tPa-induced thrombolysis and subsequent reduction of ischemic brain damage. How- * Research Engineer and Head, Universite´ de Caen - Basse Nor- ever, in contrast to xenon, postischemic nitrous oxide in- mandie, Centre Universitaire de Ressources Biologiques, Caen, France. creased brain hemorrhage and barrier dysfunction. † Research Scientist, Universite´ Laval, Centre Hospitalier Universitaire Affilie´Hoˆtel-Dieu Le´vis, Le´vis, Que´bec, Canada; Universite´ Laval, Cen- tre de Recherche Universite´ Laval Robert-Giffard, Que´bec, Que´bec, Canada. ‡ Senior Research Scientist, Universite´ de Caen - Basse Nor- ischemic stroke. Although intraischemic xenon inhibits tPA- mandie, ERTi 1083, UMR 6232, Caen, France; Centre National de la induced thrombolysis and subsequent reduction of brain Recherche Scientifique, UMR 6232, Caen, France. § Lieutenant, United States Medical Services Corps, Navy Experimental Diving Unit, Panama damage, postischemic xenon virtually suppresses both isch- City, Florida. ࿣ Research Director, Institut de Recherche Biome´dicale emic brain damage and tPA-induced brain hemorrhages and des Arme´es, Antenne Toulon, Toulon, France. # Professor of Neuro- disruption of the blood–brain barrier. The authors investi- sciences, Universite´ de Caen - Basse Normandie, ERTi 1083, UMR 6232; Centre National de la Recherche Scientifique, UMR 6232; Universite´ gated whether nitrous oxide could also interact with tPA. Laval, Centre Hospitalier Universitaire Affilie´Hoˆtel-Dieu Le´vis; Methods: The authors performed molecular modeling of Universite´ Laval, Centre de Recherche Universite´ Laval Robert- nitrous oxide binding on tPA, characterized the concentra- Giffard, Que´bec. tion-dependent effects of nitrous oxide on tPA enzymatic Received from Universite´ de Caen - Basse Normandie, ERTi 1083, UMR 6232, Caen, France; Centre National de la Recherche Scientifique, and thrombolytic activity in vitro, and investigated the effects UMR 6232, Caen, France; Universite´ Laval, Centre Hospitalier Univer- of intraischemic and postischemic nitrous oxide in a rat sitaire Affilie´Hoˆtel-Dieu Le´vis, Le´vis, Que´bec, Canada; and Universite´ model of thromboembolic acute ischemic stroke. Laval, Centre de Recherche Universite´ Laval Robert-Giffard, Que´bec, Que´bec, Canada. Submitted for publication March 27, 2011. Accepted Results: The authors demonstrate nitrous oxide is a tPA inhib- for publication July 22, 2011. Supported by Universite´ de Caen, Caen, itor, intraischemic nitrous oxide dose-dependently inhibits tPA- France; the Centre National de la Recherche Scientifique, Paris, France; induced thrombolysis and subsequent reduction of ischemic the Direction Ge´ne´rale de l’Armement, Paris, France; and NNOXe Pharmaceuticals, Quebec City, Quebec, Canada. NNOXe Pharmaceu- brain damage, and postischemic nitrous oxide reduces ischemic ticals (Quebec City, Beubec, Canada) has patent applications on the brain damage, but in contrast with xenon, it increases brain use of inert gases and tPA for treating ischemia. The authors have hemorrhages and disruption of the blood–brain barrier. declared that no financial conflicts of interests exist. Lt. Colomb is a military service member, and this work was prepared as part of his Conclusions: In contrast with previous studies using me- official duties. The views expressed in this article are those of the chanical acute stroke models, these data obtained in a clini- author and do not reflect the official policy or position of the Depart- cally relevant rat model of thromboembolic stroke indicate ment of the Navy, Department of Defense, or the U.S. Government. that nitrous oxide should not be considered a good candidate Address correspondence to Dr. Abraini: ERTi 1083, UMR 6232, Universite´ de Caen, CNRS, CEA, Boulevard Henri Becquerel, Centre agent for treating acute ischemic stroke compared with xenon. CYCERON, 14074 Caen cedex, France, or Centre de Recherche Universite´ Laval Robert-Giffard, Quebec, Quebec, Canada. abraini@ cyceron.fr or [email protected]. Information on pur- CUTE ischemic stroke through thromboembolism re- chasing reprints may be found at www.anesthesiology.org or on the A mains a major cause of acute mortality and chronic masthead page at the beginning of this issue. ANESTHESIOLOGY’s morbidity. The most common approved therapy of acute articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue. ischemic stroke is thrombolysis by the recombinant form of Copyright © 2011, the American Society of Anesthesiologists, Inc. Lippincott the serine protease human tissue-type plasminogen activator 1 Williams & Wilkins. Anesthesiology 2011; 115:1044–53 (tPA). Although recombinant tPA has benefited ischemic Anesthesiology, V 115 • No 5 1044 November 2011 CRITICAL CARE MEDICINE stroke patients if given within 4.5 h of symptoms,2–4 adverse used for surgery, all rats were housed individually. Light was effects, primarily brain hemorrhages and disruption of the maintained on a light–dark reverse cycle, with lights on from blood–brain barrier integrity through tPA-mediated proteo- 8:00 PM to 8:00 AM. lytic processes, have been reported.3–7 In contrast, strategies of neuroprotection by the use of glutamatergic receptor an- Modeling of the Binding Site of Nitrous Oxide within the tagonists to counteract ischemia-induced overstimulation of S1 Pocket of tPA the N-methyl-D-aspartate (NMDA) glutamatergic receptors, We performed the structural superposition of the catalytic whose postsynaptic activation is known as a critical event in domain of tPA (Protein Data Bank entry: 1A5H)30 to elas- neuronal death induced by acute ischemic stroke,8–10 have not tase in complex with nitrous oxide with the software PyMOL been proven efficient in patients experiencing ischemic insults, (DeLano Scientific, San Carlos, CA). The root mean square Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/115/5/1044/452771/0000542-201111000-00027.pdf by guest on 25 September 2021 primarily because these compounds produced intolerable neu- deviation between the catalytic domain of tPA and elastase rotoxic and psychotomimetic side effects.11,12 Taken together, was 1.5 Å for 221 aligned carbon ␣ (C␣). this has led to the conclusion that methods of neuroprotection 13 that could prevent tPA toxicity are needed. tPA Catalytic Activity Assay with Nitrous Oxide During the past decade, much attention has been paid to We assessed the effects of nitrous oxide on the catalytic effi- the potentially neuroprotective properties of the remarkably ciency of tPA by using the initial rate method. The recombinant safe anesthetic gases xenon and nitrous oxide. Both gases form of human tPA (Actilyse௡; Boehringer Ingelheim, Ingel- share many pharmacologic properties as antagonists of the heim am Rhein, Germany) and murine tPA (ref. IRTPA; 14–17 NMDA and nicotinic acetylcholine receptor, activators Innovative Research, Novi, MI) and their specific chromogenic ϩ 18 of the TREK-1 two-pore–domain K channel, and en- substrate methylsulfonyl-D-phenyl-glycil-arginine-7-amino-4- 19,20 zyme inhibitors. Preclinical evidence in rodents has methylcoumarin acetate (Spectrozyme௡ XF, product 444; proven that these gases may have effective neuroprotective American Diagnostica, Stamford, CT) were separately diluted 14 properties by reducing excitotoxic neuronal death, me- in 1 ml distilled water in 1.5-ml sterile tubes. Each tube contain- chanical middle cerebral artery occlusion (MCAO)-induced ing 0.4 ␮M tPA or 10 ␮M tPA substrate was saturated for 20 21–25 brain damage, neonatal hypoxic–ischemic brain dam- min at a flow rate of 60–80 ml/min with nitrous oxide of 25–75 26,27 age, and cardiopulmonary bypass-induced neurologic vol% or medical air composed of 25% oxygen and 75% nitro- 28 and neurocognitive dysfunction, with no adverse side ef- gen as described previously.29 We assessed the catalytic effi- fects when used at subanesthetic concentrations. This has led ciency of human and murine tPA (N ϭ 3, n ϭ 12, per concen- to many thinking that clinical trials could be initiated in tration) in the presence of air or nitrous oxide by incubating 50 acute stroke patients in the near future. However, a recent ␮l tPA with 50 ␮l substrate at 37°C using a spectrofluorometer study performed in a rat model of thromboembolic stroke
Load more

Recommended publications
  • Profil D'effets Indésirables Des Antagonistes R-NMDA
    Profil d’effets indésirables des antagonistes R-NMDA : analyse de clusters des signaux de disproportionnalité extraits de Vigibase® Nhan-Taï Pierre Ly To cite this version: Nhan-Taï Pierre Ly. Profil d’effets indésirables des antagonistes R-NMDA : analyse de clusters des signaux de disproportionnalité extraits de Vigibase®. Sciences pharmaceutiques. 2019. dumas- 03039996 HAL Id: dumas-03039996 https://dumas.ccsd.cnrs.fr/dumas-03039996 Submitted on 4 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il n’a pas été réévalué depuis la date de soutenance. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D’autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact au SID de Grenoble : [email protected] LIENS LIENS Code
    [Show full text]
  • From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J
    REVIEW The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J. David Jentsch, Ph.D., and Robert H. Roth, Ph.D. Administration of noncompetitive NMDA/glutamate effects of these drugs are discussed, especially with regard to receptor antagonists, such as phencyclidine (PCP) and differing profiles following single-dose and long-term ketamine, to humans induces a broad range of exposure. The neurochemical effects of NMDA receptor schizophrenic-like symptomatology, findings that have antagonist administration are argued to support a contributed to a hypoglutamatergic hypothesis of neurobiological hypothesis of schizophrenia, which includes schizophrenia. Moreover, a history of experimental pathophysiology within several neurotransmitter systems, investigations of the effects of these drugs in animals manifested in behavioral pathology. Future directions for suggests that NMDA receptor antagonists may model some the application of NMDA receptor antagonist models of behavioral symptoms of schizophrenia in nonhuman schizophrenia to preclinical and pathophysiological research subjects. In this review, the usefulness of PCP are offered. [Neuropsychopharmacology 20:201–225, administration as a potential animal model of schizophrenia 1999] © 1999 American College of is considered. To support the contention that NMDA Neuropsychopharmacology. Published by Elsevier receptor antagonist administration represents a viable Science Inc. model of schizophrenia, the behavioral and neurobiological KEY WORDS: Ketamine; Phencyclidine; Psychotomimetic; widely from the administration of purportedly psychot- Memory; Catecholamine; Schizophrenia; Prefrontal cortex; omimetic drugs (Snyder 1988; Javitt and Zukin 1991; Cognition; Dopamine; Glutamate Jentsch et al. 1998a), to perinatal insults (Lipska et al. Biological psychiatric research has seen the develop- 1993; El-Khodor and Boksa 1997; Moore and Grace ment of many putative animal models of schizophrenia.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,902,815 Olney Et Al
    USOO5902815A United States Patent (19) 11 Patent Number: 5,902,815 Olney et al. (45) Date of Patent: May 11, 1999 54 USE OF 5HT2A SEROTONIN AGONISTS TO Hougaku, H. et al., “Therapeutic effect of lisuride maleate on PREVENT ADVERSE EFFECTS OF NMDA post-stroke depression” Nippon Ronen Igakkai ZaSShi 31: RECEPTOR HYPOFUNCTION 52-9 (1994) (abstract). Kehne, J.H. et al., “Preclinical Characterization of the Poten 75 Inventors: John W. Olney, Ladue; Nuri B. tial of the Putative Atypical Antipsychotic MDL 100,907 as Farber, University City, both of Mo. a Potent 5-HT2A Antagonist with a Favorable CNS Saftey Profile.” The Journal of Pharmacology and Experimental 73 Assignee: Washington University, St. Louis, Mo. Therapuetics 277: 968–981 (1996). Maurel-Remy, S. et al., “Blockade of phencyclidine-induced 21 Appl. No.: 08/709,222 hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors' European Jour 22 Filed: Sep. 3, 1996 nal of Pharmacology 280: R9–R11 (1995). 51) Int. Cl. ........................ A61K 31/445; A61K 31/54; Olney, J.W., et al., “NMDAantagonist neurotoxicity: Mecha A61K 31/135 nism and prevention,” Science 254: 1515–1518 (1991). 52 U.S. Cl. .......................... 514/285; 514/315; 514/318; Olney, J.W., et al., “Glutamate receptor dysfunction and 514/646 schizophrenia.” Arch. Gen. Psychiatry 52:998-1007 (1995). 58 Field of Search ............................. 514/285; 314/315, Pulvirenti, L. et al., “Dopamine receptor agonists, partial 314/318, 646 agonists and psychostimulant addiction' Trends Pharmacol Sci 15: 374-9 (1994). 56) References Cited Robles, R.G. et al., “Natriuretic Effects of Dopamine Agonist Drugs in Models of Reduced Renal Mass” Journal of U.S.
    [Show full text]
  • A Radical Approach to Stroke Therapy
    Commentary A radical approach to stroke therapy James McCulloch* and Deborah Dewar Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, Glasgow G61 1QH, United Kingdom troke is a major cause of death and readily crosses the blood–brain barrier, (mitogen-activated protein kinases͞ Sdisability throughout the developed to augment endogenous brain ascorbic ERK1͞2). During ischemia, ERK1͞2 are world. Cerebrovascular disease ranks acid levels by up to 2 mM. However, in dephosphorylated, and there is a signif- third after cancer and heart disease as a the brain, ascorbic acid levels are heter- icant increase in ERK1͞2 phosphoryla- cause of death in the European Union ogeneous and highly compartmental- tion during reperfusion after forebrain and the U.S. The economic and social ized. In the rat, normal neuronal, glial, ischemia. Neurons and oligodendrocytes burdens of stroke are not consequences and cerebrospinal fluid levels of ascorbic at the margin of a focal ischemic lesion of mortality; they are imposed by the acid are Ϸ10 mM, 1 mM, and 0.5 mM, display increased MEK1͞2, indicating large majority of stroke patients who respectively (3). The antioxidant effects that this signaling pathway is activated survive but are physically and mentally of ascorbic acid at all of these sites within after ischemia and reperfusion in vivo disabled by stroke-induced brain dam- the brain could contribute to the efficacy (8). If MEK1͞2 is inhibited by the novel age. In the U.S., less than 2% of stroke of this agent in ischemia. Brain ascorbic agent, U0126, the extent of brain damage patients benefit from access to early acid levels are highly dynamic (although is reduced after either forebrain or focal thrombolysis, which removes the primary under rigorous homeostatic control), ischemia (2).
    [Show full text]
  • Neu2000, an NR2B-Selective, Moderate NMDA Receptor
    Drug News & Perspectives 2010, 23(9): 549-556 THOMSON REUTERS LOOKING AHEAD Targeting both NMDA receptors and free NEU2000, AN NR2B-SELECTIVE, radicals may provide MODERATE NMDA RECEPTOR enhanced ANTAGONIST AND POTENT SPIN neuroprotection against TRAPPING MOLECULE FOR hypoxic-ischemic injury. STROKE confer substantial neuroprotection in ani- by Sung Ig Cho, Ui Jin Park, mal models of stroke have failed to show SUMMARY Jun-Mo Chung and Byoung Joo Gwag beneficial effects in clinical trials for stroke. Excess activation of ionotropic gluta- Free radicals mediate an additional route of mate receptors, primarily N-methyl-D- Stroke is a cerebrovascular injury caused by neuronal cell death after ischemia and aspartate (NMDA) receptors and free the interruption of blood flow to the brain reperfusion. Several antioxidants have radicals, evoke nerve cell death follow- due to thrombosis, embolic particles or advanced to clinical trials including edar- ing hypoxic-ischemic brain injury in var- blood vessel bursts. Stroke is the leading avone, a hydroxyl radical scavenger that has ious animal models. However, clinical cause of serious, long-term disability in shown beneficial effects in patients with trials in stroke patients using NMDA adults and the second leading cause of transient ischemia and which was approved receptor antagonists have failed to death in the U.S. and Europe (1). Rates of as a neuroprotective drug in Japan and show efficacy primarily due to the limit- stroke mortality and burden are more China. ed therapeutic time window for neuro- affected in low-income countries including protection and a narrow therapeutic NMDA receptor antagonists and antioxi- eastern Europe, northern Asia and central index.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Understanding History, and Not Repeating It. Neuroprotection For
    Clinical Neurology and Neurosurgery 129 (2015) 1–9 Contents lists available at ScienceDirect Clinical Neurology and Neurosurgery jo urnal homepage: www.elsevier.com/locate/clineuro Review Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview a a b b,c a,b,c,d,∗ Stephen Grupke , Jason Hall , Michael Dobbs , Gregory J. Bix , Justin F. Fraser a Department of Neurosurgery, University of Kentucky, Lexington, USA b Department of Neurology, University of Kentucky, Lexington, USA c Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA d Department of Radiology, University of Kentucky, Lexington, USA a r t i c l e i n f o a b s t r a c t Article history: Background: Neuroprotection for ischemic stroke is a growing field, built upon the elucidation of the Received 17 April 2014 biochemical pathways of ischemia first studied in the 1970s. Beginning in the early 1990s, means by Received in revised form 7 November 2014 which to pharmacologically intervene and counteract these pathways have been sought, though with Accepted 13 November 2014 little clinical success. Through a comprehensive review of translations from laboratory to clinic, we aim Available online 3 December 2014 to evaluate individual mechanisms of action, while highlighting potential barriers to success that will guide future research. Keywords: Methods: The MEDLINE database and The Internet Stroke Center clinical trials registry were queried Acute stroke Angiography for trials involving the use of neuroprotective agents in acute ischemic stroke in human subjects. For the purpose of the review, neuroprotective agents refer to medications used to preserve or protect the Brain ischemia Drug trials potentially ischemic tissue after an acute stroke, excluding treatments designed to re-establish perfusion.
    [Show full text]
  • Possible Protective Effect Or Harmful of Ketamine on Isquemia-Induced Acute Kidney Injury in a Pediatric Murine Model
    Open Access Austin Journal of Anesthesia and Analgesia Special Article - Pediatric Anesthesiology Possible Protective Effect or Harmful of Ketamine on Isquemia-Induced Acute Kidney Injury in a Pediatric Murine Model Acosta-Murillo NR and Dueñas Gómez Z* Department of Physiological Sciences, National Abstract University of Colombia, Colombia The association between Ketamine and renal function begins in animal *Corresponding author: Dueñas Gómez Z, models, since the 1970s, particularly in relation to the effects on renal blood Department of Physiological Sciences, Division of flow [1,2]. Factors on renal hemodynamics such as decreased cardiac output Physiology, National University of Colombia, Bogotá, and blood pressure, sympathetic nerve stimulation and catecholamine release Colombia and, increased renin, angiotensin and vasopressin were involved [3]. From this century, the presence of N-Methyl-D-Aspartate Receptors (NMDA-R) outside Received: April 26, 2016; Accepted: June 01, 2016; the Central Nervous System (CNS) [4] where they had been initially identified Published: June 06, 2016 has been proposed, whereby the existence of the NMDA-R in the kidney and its functional role becomes important [5,6] in this way, the possible effects of NMDA-R antagonists, such as ketamine. Keywords: L-Glutamate; NMDA receptors; Renal function, Ketamine; Acute kidney injury; Ischemia/Reperfusion Abbreviations Α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) receptor [8,9]. NMDA-R is large heterotetrameric membrane protein L-Glu: L-Glutamate; NMDA-R: N-Methyl-D-Aspartate complexes with a high permeability to calcium, which triggers a series Receptors; iGluRs: Ionotropic Glutamate Receptors; mGluRs: of calcium mediated intracellular events that have an outstanding Metabotropic Glutamate Receptors; AMPA: Α-Amino-3-Hydroxy- role in many physiological and pathological processes.
    [Show full text]
  • Dextromethorphan in Chronic Pain: a Disappointing Update
    Reviews Dextromethorphan in Chronic Pain: A Disappointing Update Ron Ben-Abraham MD1 and Avi A Weinbroum MD1,2 1Department of Anesthesiology and Critical Care and 2Post-Anesthesia Care Unit, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel Key words: chronic pain, N-methyl-D-aspartate, antagonists, dextromethorphan IMAJ 2000;2:708710 Chronic pain syndromes have traditionally been treated by sometimes lead to side effects like agitation, hallucinations, various regimens of opioids, non-steroidal anti-inflammatory somnolence, nausea and vomiting [1315]. This is one of the drugs, and regional blocks. However, opioids-related respi- reasons why at the present time the clinical use of NMDA- ratory depression and NSAID-associated bleeding tendency receptor antagonists is limited to the FDA-approved DM, or renal impairment can sometimes limit the use of these ketamine or amantadine. However, since ketamine affinity to medications, while the efficacy of regional block fades over the NMDA receptors is high, its administration even with time. Recently, the N-methyl-D-aspartate receptor antago- the newly tested oral form [16] is frequently accompanied nists were shown to alleviate somatic and neuropathic pain by unbearable dysphoric effects. In addition, the need to sensation in both animal and human models [15]. NMDA administer it intravenously or even subcutaneously makes it receptors are located in the posterior column of the spinal less attractive as a potential antinociceptive agent for cord where pain generated by peripheral nociceptive stimuli patients who suffer from chronic pain. DM, which was and conveyed via sensory fibers is relayed centrally [6]. One originally synthesized as a pharmacological alternative to of the antagonistic compounds is dextromethorphan, which morphine, was later used as an anti-tussive (in syrup possesses low affinity to the receptor and acts non- preparations at adult doses of 10 to 30 mg three to six times competitively.
    [Show full text]
  • Glutamate NMDA Receptors in Pathophysiology And
    ® Postepy Hig Med Dosw (online), 2011; 65: 338-346 www.phmd.pl e-ISSN 1732-2693 Review Received: 2011.02.07 Accepted: 2011.05.11 Glutamate NMDA receptors in pathophysiology and Published: 2011.06.07 pharmacotherapy of selected nervous system diseases Rola receptorów NMDA w patofizjologii i farmakoterapii wybranych chorób układu nerwowego Łukasz Dobrek, Piotr Thor Department of Pathophysiology, Jagiellonian University Medical College Cracow, Poland Summary Glutamate is the basic excitatory neurotransmitter acting via N-methyl-D-aspartate receptors (NMDARs). It co-regulates many important physiological functions, including learning, memo- ry, and behaviour. An excess of glutamate, as well as NMDAR over-activity, produce pathologi- cal effects. Glutamate-related neurotoxicity is involved in the pathogenesis of many neurological conditions. This article briefly describes the role of the glutamate system in the pathophysiology of brain ischemia, selected neurodegenerative disorders, and schizophrenia. It also reviews the current and potential future status of agents targeting NMDARs in neuropsychopharmacology. Key words: glutamate • NMDA receptors (NMDARs) • excitotoxicity • NMDAR antagonists Streszczenie Glutaminian jest podstawowym neuroprzekaźnikiem pobudzającym, który działa na receptory NMDA. Związek ten jest współodpowiedzialny za regulowanie wielu ważnych fizjologicznych funkcji, wliczając w to uczenie się, pamięć i zachowanie. Nadmiar glutaminianu i nadaktywność receptorów NMDARs wywołuje patologiczne zmiany. Zjawisko neurotoksyczności
    [Show full text]
  • Some Distorted Thoughts About Ketamine As a Psychedelic and a Novel Hypothesis Based on NMDA Receptor-Mediated Synaptic Plasticity
    Neuropharmacology xxx (2018) 1e11 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Invited review Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity Rachael Ingram a, Heather Kang b, c, d, Stafford Lightman b, David E. Jane c, * Zuner A. Bortolotto c, Graham L. Collingridge c, d, David Lodge c, 1, Arturas Volianskis a, b, , 1 a Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK b School of Clinical Sciences, University of Bristol, Bristol, UK c Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK d Dept Physiology, University of Toronto and Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada article info abstract Article history: Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, Received 7 April 2018 which may arise from a combination of several inter-related actions. Firstly, reductions of the contri- Received in revised form bution of NMDA receptors to afferent information from external and internal sensory inputs may distort 27 May 2018 sensations and their processing in higher brain centres. Secondly, reductions of NMDA receptor- Accepted 5 June 2018 mediated excitation of GABAergic interneurons can result in glutamatergic overactivity. Thirdly, limbic Available online xxx cortical disinhibition may indirectly enhance dopaminergic and serotonergic activity. Fourthly, inhibition of NMDA receptor mediated synaptic plasticity, such as short-term potentiation (STP) and long-term Keywords: fi Psychedelics potentiation (LTP), could lead to distorted memories.
    [Show full text]